Recent in vivo studies showed that the use of MCM2/CA9 inhibitors, such as ciprofloxacin and acetazolamide, respectively, in combination with cisplatin, improve mice overall survival and reduce tumor nodule growth [78]. Here, CA9 is linked to neoplasm.